LIK066, a Dual SGLT1/2 Inhibitor, Reduces Weight and Improves Multiple Incretin Hormones in Clinical Proof-of-Concept Studies in Obese Patients With or Without Diabetes

Authors
Category Primary study
ConferenceDiabetes
Year 2018
This article has no abstract
Epistemonikos ID: cebe625cd7b0684ff5c9aedf54acfbdddc15b21e
First added on: Apr 04, 2026